微小RNA在糖尿病肾病中的研究进展(5)
[25] Eissa S，Matboli M，Bek MM. Clinical verification of a novel urinary microRNA panal：133b，-342 and -30 as biomarkers for diabetic nephropathy identified by bioinformatics analysis [J]. Biomed Pharmacother，2016，83：92-99.
[26] Roux M，Perret C，Feigerlova E. Plasma levels of hsa-miR-152-3p are associated with diabetic nephropathy in patients with type 2 diabetes [J]. Nephrol Dial Transplant，2018，33(12)：2201-2207.
[27] Barutta F，Bruno G，Matullo G. MicroRNA-126 and micro-/macrovascular complications of type 1 diabetes in the EURODIAB Prospective Complications Study [J]. Acta Diabetol，2017，54(2)：133-139.
[28] Kato M. Noncoding RNAs as therapeutic targets in early stage diabetic kidney disease [J]. Kidney Res Clin Pract，2018，37(3)：197-209.
[29] Roos M，Pradere U，Ngondo RP，et al. A Small-Molecule Inhibitor of Lin28 [J]. ACS Chem Biol，2016，11(10)：2773-2781.
[30] Liu R，Das B，Xiao W，et al. A Novel Inhibitor of Homeodomain Interacting Protein Kinase 2 Mitigates Kidney Fibrosis through Inhibition of the TGF-beta1/Smad3 Pathway [J]. J Am Soc Nephrol，2017，28(7)：2133-2143.
(收稿日期：2020-03-12), 百拇医药(田莎莎 杨晓鹏 郭珲)
[26] Roux M，Perret C，Feigerlova E. Plasma levels of hsa-miR-152-3p are associated with diabetic nephropathy in patients with type 2 diabetes [J]. Nephrol Dial Transplant，2018，33(12)：2201-2207.
[27] Barutta F，Bruno G，Matullo G. MicroRNA-126 and micro-/macrovascular complications of type 1 diabetes in the EURODIAB Prospective Complications Study [J]. Acta Diabetol，2017，54(2)：133-139.
[28] Kato M. Noncoding RNAs as therapeutic targets in early stage diabetic kidney disease [J]. Kidney Res Clin Pract，2018，37(3)：197-209.
[29] Roos M，Pradere U，Ngondo RP，et al. A Small-Molecule Inhibitor of Lin28 [J]. ACS Chem Biol，2016，11(10)：2773-2781.
[30] Liu R，Das B，Xiao W，et al. A Novel Inhibitor of Homeodomain Interacting Protein Kinase 2 Mitigates Kidney Fibrosis through Inhibition of the TGF-beta1/Smad3 Pathway [J]. J Am Soc Nephrol，2017，28(7)：2133-2143.
(收稿日期：2020-03-12), 百拇医药(田莎莎 杨晓鹏 郭珲)